The Zhitong Finance App learned that China Galaxy Securities released a research report saying that after dual antibodies and ADC, TCE is becoming a new trading hotspot in the field of innovative drugs. China has become an important source of global TCE innovation. As of mid-2026, Chinese pharmaceutical companies have promoted more than 10 TCE projects, covering three-antibody TCE, shielded TCE, 2+1 structures, etc. TCE has been commercialized, various hematoma products have been approved, SCLC has random OS confirmation, and MM has entered earlier treatment. It is recommended to focus on solid tumors, hematomas, and targets related to immunity.
The main views of China Galaxy Securities are as follows:
TCE innovative drug-related deals have broken out, and it is expected to become a new cradle for the birth of major new drugs
Following dual antibodies and ADC, TCE is becoming a new trading hotspot in the field of innovative drugs. As the racetrack continues to heat up, BD competition for high-quality TCE assets has accelerated markedly. In 2025 alone, 10 Chinese pharmaceutical companies will launch TCE projects overseas, with a cumulative potential transaction amount of more than 7 billion US dollars. On September 1, 2026, Xiansheng Zaiming and Roche reached an exclusive global licensing agreement for CD79a/CD19/CD3 tri-antibody Sim0660. Xiansheng then Ming can obtain a down payment of 75 million US dollars, with a total transaction value of up to 1.53 billion US dollars. SIM0660 is currently still in the pre-clinical phase. On October 2, Abbott Biotech and Novartis reached an agreement to grant Novartis ABO2203 (mRNA-coded CD19/CD3 TCE pipeline) with exclusive licensing options for developing other potential projects based on its proprietary RNA platform, with a down payment of US$575 million, and a total transaction amount of up to US$7.775 billion.
The TCE indication landscape continues to expand: based on hematomas, solid tumors break the game, and take over
TCE has completed technical and commercial double verification of hematoma. The targets focus on CD19/CD20 and BCMA/GPRC5D, and the indications are gradually advancing to the front line. Tarlatamab's randomized phase III overall survival benefit in 2025 advanced TCE treatment to clinical verification; there are various TCE layouts for lung cancer, neuroendocrine cancer, prostate cancer, etc. around the world. Furthermore, TCE can deeply remove autoreactive B-cells/plasma cells by targeting CD19/CD20/BCMA and achieve immune rearrangement, which is expected to fundamentally change the treatment paradigm for autoimmune diseases such as SLE and RA, but it is still in the exploration stage, and no products have been approved.
China's strength: the rise of TCE platform companies and the wave of internationalization
China has become an important source of global TCE innovation. As of mid-2026, Chinese pharmaceutical companies have promoted more than 10 TCE projects, covering three-antibody TCE, shielded TCE, 2+1 structures, etc. Zejing Pharmaceuticals, Weilizhibo, and Deqi Pharmaceuticals are important representative companies in the TCE field. In addition, Cinda Biotech (IBI3003 BCMA/GPRC5D/CD3 Phase III), Connor (CM336 authorized to Gilead, total amount of US$2.175 million), Zhixiang Jintai (GR1803 authorized to Cullinan, total amount of US$712 million), and Platinum Pharmaceuticals (HBM7022 authorized to AZ; HBM7020 authorized to Otsuka, total amount of US$670 million) all occupy important positions.
Risk warning: 1. Insufficient pharmaceutical consumption due to increased macroeconomic pressure; 2. Medical insurance payments for innovative drugs fell short of expectations; 3. Global order transfers brought about by geopolitics; 4. Reduced procurement or fees exceeded market expectations.